Risk factors for recurrent wheezing in preterm infants who received prophylaxis with palivizumab

Manini, Mariana Bueno; Matsunaga, Natasha Yumi; Gianfrancesco, Lívea; Oliveira, Marina Simões; Carvalho, Maria Rosa Vieira de; Ribeiro, Gisleine Leila Martins Tengler; Morais, Eliane de Oliveira; Ribeiro, Maria Angela Gonçalves O; Morcillo, André Moreno; Ribeiro, José Dirceu; Toro, Adyléia Aparecida Dalbo Contrera.
J. bras. pneumol ; 47(5): e20210157, 2021. tab, graf
Artigo em Inglês | LILACS | ID: biblio-1346399

Documentos relacionados

  1. Risk factors for recurrent wheezing in preterm infants who received prophylaxis with palivizumab.
  2. Risk factors for hospitalisation due to respiratory syncytial virus infection in children receiving prophylactic palivizumab.
  3. Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia.
  4. Full compliance with Respiratory syncytial virus prophylaxis was associated with fewer respiratory-related hospital admissions in preterm children: A cohort study.
  5. Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children.
  6. Increasing Rates of RSV Hospitalization among Preterm Infants: A Decade of Data.
  7. Access to palivizumab among children at high risk of respiratory syncytial virus complications in English hospitals.
  8. RSV Prevention - Breakthroughs and Challenges.
  9. A Systematic Review of European Clinical Practice Guidelines for Respiratory Syncytial Virus Prophylaxis.
  10. An outbreak of RSV infections in a neonatology clinic during the RSV-season.